Glenmark gets China approval for RYALTRIS nasal spray

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1838.10

prior close

₹1840.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-1.8% vs market

Pharmaceuticals peers, median of 157sector-0.2%-1.1% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Midcap 150 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.5

15m

-0.6

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.4-1.8-0.2-1.1

Next day

+0.6+1.2-0.6+0.5+0.2

+2.8+0.9+1.9+0.6+2.2

+3.1+0.9+2.2+0.3+2.8

+1.6+1.6-0.0+0.2+1.4

-0.2+1.0-1.1-0.6+0.5

+2.5+1.3+1.3-1.1+3.7

15d

+7.7+0.9+6.8-2.1+9.8

+6.2-1.1+7.2-3.2+9.4

+9.6-0.8+10.4-5.9+15.5

+9.7+1.1+8.6-6.4+16.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

China drug regulator NMPA has approved Glenmark's RYALTRIS nasal spray for allergic rhinitis in adults and children. The approval came with zero supplementation requests, backed by a Phase III trial of 535 patients in China showing better efficacy than standard treatments. RYALTRIS is already approved in the US, EU, UK, Australia, South Korea and Russia. China sales will be handled by Grand Pharmaceuticals under an exclusive licensing deal. In FY25, the product was launched in 11 new markets and is now sold across 45 countries.

Likely market impact

Positive for respiratory portfolio. China is called a priority market, but commercialization is via partner Grand Pharma, so revenue contribution may be gradual.